Clinical bottom line
Novel inhaled antiviral therapies represent a promising, yet still investigational, approach to preventing viral-triggered exacerbations in chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Respiratory viral infections are a major precipitant of exacerbations, which contribute substantially to morbidity, healthcare utilization, and disease progression. Early-phase studies and preclinical data suggest that targeted inhaled antivirals could reduce viral load in the airways, potentially mitigating exacerbation frequency and severity. However, robust clinical trial evidence demonstrating clear efficacy and safety in chronic respiratory populations remains limited. Clinicians should remain informed about emerging data but continue to rely primarily on established pharmacologic and non-pharmacologic strategies for exacerbation prevention at present.
What the evidence shows
Respiratory viral infections, including rhinoviruses, influenza, and coronaviruses, are well-recognized triggers of exacerbations in chronic respiratory diseases such as COPD and asthma (Role of Respiratory Viral Infection at Exacerbation, 2008). These exacerbations accelerate lung function decline and increase hospitalization risk. Current preventive pharmacotherapies focus on bronchodilators, inhaled corticosteroids, and biologics, which indirectly reduce exacerbation risk but do not specifically target viral pathogens (Beeh et al., 2016; Lee et al., 2025).
Recent advances in antiviral drug development have led to novel inhaled formulations designed to deliver high local concentrations of antiviral agents directly to the respiratory tract, aiming to inhibit viral replication early in infection (Majumdar et al., 2023). Preclinical in vitro and in vivo models demonstrate that inhaled antivirals can reduce viral load and inflammatory responses in airway tissues (Nitharwal et al., 2023). These findings provide a mechanistic rationale for their potential use in preventing viral exacerbations.
However, clinical data remain sparse. Most human studies to date have been small, early-phase trials primarily assessing safety, pharmacokinetics, and antiviral activity rather than definitive clinical outcomes. No large-scale randomized controlled trials have yet established the efficacy of inhaled antivirals in reducing exacerbation frequency or improving long-term outcomes in COPD or asthma populations. Furthermore, existing antiviral therapies approved for systemic use (e.g., oseltamivir) have limited efficacy when administered after symptom onset and are not routinely used prophylactically in chronic respiratory disease.
Vitamin and adjunctive therapies have also been explored for their antiviral and immunomodulatory effects, but these remain experimental and are not substitutes for targeted antiviral agents (Jain et al., 2024). Ethical considerations around antiviral use, including resistance development and patient selection, require further study (Papatheodoridis et al., 2008).
Caveats and uncertainty
The current evidence base for inhaled antiviral therapies in chronic respiratory disease exacerbation prevention is preliminary and hypothesis-generating rather than confirmatory. Key uncertainties include:
- Lack of large, well-powered randomized controlled trials demonstrating clinical efficacy in reducing exacerbations or hospitalizations.
- Limited data on long-term safety and tolerability of inhaled antiviral agents in populations with chronic lung disease.
- Variability in viral pathogens causing exacerbations, which may necessitate broad-spectrum or combination antiviral approaches.
- Potential development of viral resistance with widespread antiviral use.
- Unclear optimal timing and patient selection criteria for prophylactic or early therapeutic inhaled antiviral administration.
Given these gaps, inhaled antivirals should not yet replace established preventive pharmacotherapies or vaccination strategies.
How this may change practice
If ongoing and future clinical trials confirm the efficacy and safety of inhaled antiviral therapies, they could become an important adjunct in the prevention of viral exacerbations in chronic respiratory diseases. This would represent a paradigm shift from indirect modulation of airway inflammation to direct antiviral intervention at the site of infection. Potential practice implications include:
- Incorporation of inhaled antivirals into exacerbation prevention protocols, especially during viral season or outbreaks.
- Personalized treatment strategies targeting patients with frequent viral-triggered exacerbations.
- Reduced reliance on systemic corticosteroids and antibiotics, potentially lowering adverse effects and resistance.
- Integration with existing vaccination and antiviral stewardship programs.
Until such evidence emerges, clinicians should continue to emphasize guideline-directed pharmacologic therapies, vaccination, and non-pharmacologic measures such as smoking cessation and infection control.